CBSET Inc., a nonprofit research institute based in Lexington, Mass, that specializes in the advancement of novel therapies, announced that it has expanded its preclinical research service offerings through a partnership with CILcare Inc., a contract resource organization (CRO) specializing in drug development targeting otic and hearing disorders.
CBSET and CILcare will be working together to enable biotech, pharmaceutical, and medtech companies to complete their investigational new drug (IND) package for drugs intended to target hearing and otic indications, and support safety trials with the inclusion of ototoxicity and the loss of auditory function as key parameters, according to CBSET.
“Despite the high prevalence and public health impact of hearing loss, only about one-fifth of people who could benefit from a hearing aid seek intervention. In light of this, FDA has previously taken regulatory actions intended to promote the availability and accessibility of hearing aid devices to consumers” – FDA December, 2016.
Due to the significant increase in hearing disorders, specifically in the younger population, hearing health has become a real public health priority. For this reason, CBSET and CILcare have decided to work in collaboration to catalyze the development of effective therapies to improve upon the quality of life of those affected.
CBSET and CILcare will launch their new auditory assessment services at the “Preclinical World Congress” in Boston, June 12-16. Visit the CBSET Exhibit Booth (#606) or CILcare Exhibit Booth (#103) to learn more about this relationship.